An antidote for calcium leak: Targeting molecular arrhythmia mechanisms

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 2, 2010, Pages 279-282

  Lehnart, Stephan E ^a,b   Lederer, W J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; CAFFEINE; CALCIUM BINDING PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CALSEQUESTRIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FLECAINIDE; RYANODINE RECEPTOR 2; S 107; SODIUM ION; TETRACAINE; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; CALCIUM CELL LEVEL; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; EDITORIAL; HEART ARRHYTHMIA; HUMAN; LOW DRUG DOSE; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDOTES; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; FLECAINIDE; HUMANS; MICE; RATS;

EID: 74349096329     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.11.005     Document Type: Editorial

References (31)

1. Berlin J.R., Cannell M.B., and Lederer W.J. Cellular origins of the transient inward current in cardiac myocytes. Role of fluctuations and waves of elevated intracellular calcium. Circ Res 65 (1989) 115-126
2. Eisner D.A., and Lederer W.J. Inotropic and arrhythmogenic effects of potassium-depleted solutions on mammalian cardiac muscle. J Physiol (Lond) 294 (1979) 255-277
3. Kass R.S., Lederer W.J., Tsien R.W., and Weingart R. Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibres. J Physiol (Lond) 281 (1978) 187-208
4. Lederer W.J., and Tsien R.W. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibers. J Physiol (Lond) 263 (1976) 73-100
5. Wier W.G., Cannell M.B., Berlin J.R., Marban E., and Lederer W.J. Cellular and subcellular heterogeneity of [Ca2+]i in single heart cells revealed by fura-2. Science 235 (1987) 325-328
6. Ferrier G.R., and Moe G.K. Effect of calcium on acetylstrophanthidin-induced transient depolarizations in canine Purkinje tissue. Circ Res 33 (1973) 508-515
7. Lehnart S.E., Mongillo M., Bellinger A., Lindegger N., Chen B.X., Hsueh W., et al. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118 (2008) 2230-2245
8. Lehnart S.E., Ackerman M.J., Benson Jr. D.W., Brugada R., Clancy C.E., Donahue J.K., et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 116 (2007) 2325-2345
9. Cheng H., and Lederer W.J. Calcium sparks. Physiol Rev 88 (2008) 1491-1545
10. Lehnart S., and Marks A.R. Regulation of ryanodine receptors in the heart. Circ Res 101 (2007) 746-749
11. 2+ transport. Circ Res 93 (2003) 487-490
12. 2+ spark mass. Journal of Molecular and Cellular Cardiology, in press. 2009.
13. Anno T., and Hondeghem L.M. Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ Res 66 (1990) 789-803
14. Watanabe H., Chopra N., Laver D., Hwang H.S., Davies S.S., Roach D.E., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15 (2009) 380-383
15. Knollmann B.C., Chopra N., Hlaing T., Akin B., Yang T., Ettensohn K., et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 116 (2006) 2510-2520
16. Gyorke I., Hester N., Jones L.R., and Gyorke S. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 86 (2004) 2121-2128
17. Lahat H., Pras E., Olender T., Avidan N., Ben-Asher E., Man O., et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69 (2001) 1378-1384
18. Postma A.V., Denjoy I., Hoorntje T.M., Lupoglazoff J.M., Da C.A., Sebillon P., et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 91 (2002) e21-e26
19. di Barletta M.R., Viatchenko-Karpinski S., Nori A., Memmi M., Terentyev D., Turcato F., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114 (2006) 1012-1019
20. Song L., Alcalai R., Arad M., Cordula M.W., Toka O., Conner D.A., et al. Increased calreticulin and ryanodine receptors by calsequestrin-2 (CASQ2) mutations cause catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 117 (2007) 1814-1823
21. Cerrone M., Noujaim S.F., Tolkacheva E.G., Talkachou A., O'Connell R., Berenfeld O., et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 101 (2007) 1039-1048
22. Rizzi N., Liu N., Napolitano C., Nori A., Turcato F., Colombi B., et al. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res 103 (2008) 298-306
23. Overend C.L., Eisner D.A., and O'Neill S.C. The effect of tetracaine on spontaneous Ca2+ release and sarcoplasmic reticulum calcium content in rat ventricular myocytes. J Physiol 502 (1997) 471-479
24. Trafford A.W., Sibbring G.C., Diaz M.E., and Eisner D.A. The effects of low concentrations of caffeine on spontaneous Ca release in isolated rat ventricular myocytes. Cell Calcium 28 (2000) 269-276
25. Venetucci L.A., Trafford A.W., Diaz M.E., O'Neill S.C., and Eisner D.A. Reducing ryanodine receptor open probability as a means to abolish spontaneous Ca2+ release and increase Ca2+ transient amplitude in adult ventricular myocytes. Circ Res 98 (2006) 1299-1305
26. Tanna B., Welch W., Ruest L., Sutko J.L., and Williams A.J. An anionic ryanoid, 10-O-succinoylryanodol, provides insights into the mechanisms governing the interaction of ryanoids and the subsequent altered function of ryanodine-receptor channels. J Gen Physiol 121 (2003) 551-561
27. Liu H., Atkins J., and Kass R.S. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 121 (2003) 199-214
28. Lehnart S.E. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr Opin Pharmacol 7 (2007) 225-232
29. Kimura J., Kawahara M., Sakai E., Yatabe J., and Nakanishi H. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol 79 (1999) 275-281
30. Wehrens X.H., Lehnart S.E., Reiken S.R., Deng S.X., Vest J.A., Cervantes D., et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304 (2004) 292-296
31. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788